P08581 (MET_HUMAN) Homo sapiens (Human)

Hepatocyte growth factor receptor UniProtKBInterProSTRINGInteractive Modelling

1390 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; ) Identical sequences: Homo sapiens: A0A024R759

Sequence Features

 1204Proton acceptor.
 1003Required for ligand-induced CBL-mediated ubiquitination.
 143R -> Q (in dbSNP:rs35469582). VAR_041738 dbSNP
 150H -> Y (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs1436957498). VAR_064855 dbSNP
 156S -> L (in dbSNP:rs56311081). VAR_041739 dbSNP
 168E -> D (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs55985569). VAR_041740 dbSNP
 238L -> S (in dbSNP:rs34349517). VAR_032478 dbSNP
 316I -> M (in dbSNP:rs35225896). VAR_032479 dbSNP
 320A -> V (in dbSNP:rs35776110). VAR_006285 dbSNP
 375N -> K (found in lung cancer also including cases carrying EGFR mutations; unknown pathological significance; decreased hepatocyte growth factor- activated receptor activity; decreased interaction with HGF; dbSNP:rs776693512). VAR_079370 dbSNP
 375N -> S (in dbSNP:rs33917957). VAR_032480 dbSNP
 385C -> Y (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs752055485). VAR_064856 dbSNP
 773P -> L (in gastric cancer; dbSNP:rs771333219). VAR_032481 dbSNP
 841F -> V (in DFNB97; dbSNP:rs794728016). VAR_075757 dbSNP
 970R -> C (in dbSNP:rs34589476). VAR_032482 dbSNP
 991P -> S (in gastric cancer; prolonged tyrosine phosphorylation in response to HGF/SF; transforming activity in athymic nude mice; dbSNP:rs768678989). VAR_032483 dbSNP
 992T -> I (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs56391007). VAR_032484 dbSNP
 1003Y -> S (probable disease-associated mutation found in lesional sample from a patient with sporadically occurring, unilateral osteofibrous dysplasia; somatic mutation; complete loss of ligand-induced CBL-mediated ubiquitination, resulting in protein stabilization). VAR_076585
 1092V -> I (in RCCP; constitutive autophosphorylation; dbSNP:rs786202724). VAR_032485 dbSNP
 1094H -> L (in RCCP; constitutive autophosphorylation; causes malignant transformation in cell lines). VAR_032486
 1094H -> R (in RCCP; causes malignant transformation in cell lines; dbSNP:rs121913243). VAR_032487 dbSNP
 1094H -> Y (in RCCP; constitutive autophosphorylation; causes malignant transformation in cell lines; dbSNP:rs121913244). VAR_032488 dbSNP
 1106H -> D (in RCCP; constitutive autophosphorylation; causes malignant transformation in cell lines). VAR_032489
 1131M -> T (in RCCP; germline mutation; dbSNP:rs121913668). VAR_006286 dbSNP
 1173T -> I (in HCC; dbSNP:rs121913675). VAR_032490 dbSNP
 1188V -> L (in RCCP; germline mutation; dbSNP:rs121913669). VAR_006287 dbSNP
 1195L -> V (in RCCP; somatic mutation; dbSNP:rs121913673). VAR_006288 dbSNP
 1220V -> I (in RCCP; germline mutation; dbSNP:rs121913670). VAR_006289 dbSNP
 1228D -> H (in RCCP; somatic mutation; dbSNP:rs121913671). VAR_006291 dbSNP
 1228D -> N (in RCCP; germline mutation; dbSNP:rs121913671). VAR_006290 dbSNP
 1230Y -> C (in RCCP; germline mutation; dbSNP:rs121913246). VAR_006292 dbSNP
 1230Y -> D (in RCCP; constitutive autophosphorylation; causes malignant transformation in cell lines). VAR_032491
 1230Y -> H (in RCCP; somatic mutation; dbSNP:rs121913247). VAR_006293 dbSNP
 1244K -> R (in HCC; dbSNP:rs121913677). VAR_032492 dbSNP
 1250M -> I (in HCC; dbSNP:rs121913676). VAR_032493 dbSNP
 1250M -> T (in RCCP; somatic mutation; dbSNP:rs121913245). VAR_006294 dbSNP
 1294V -> I (found in a case of cancer of unknown primary origin; the mutated receptor is still functional and can sustain the transformed phenotype; somatic mutation; dbSNP:rs1263785859). VAR_064857 dbSNP
 933-955Helical.
 1084-1092ATP.
 307-308Cleavage.
 1009-1010Breakpoint for translocation to form TPR- MET oncogene.
 95-101
 98-160
 133-141
 172-175
 298-363
 385-397
 520-538
 526-561
 529-545
 541-551
 610-624
 697-709
 964-1010Missing (in OSFD; loss of CBL-mediated destabilization). VAR_076584
 57-490Sema domain
IPR001627PF01403
 520-559Plexin repeat
IPR002165PF01437
 563-654IPT domain
IPR002909PF01833
 657-728IPT domain
IPR002909PF01833
 742-817IPT domain
IPR002909PF01833
 1079-1336Serine-threonine/tyrosine-protein kinase , catalytic domain
IPR001245PF07714

Sequence Alignments

Experimental structures

DescriptionOligo-stateLigandsStructureRangeDownloadAssess
107_A07 Fab in complex with fragment of the Met receptor Heteromer
P08581;
NAG;5lsp25-740
Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes in... Heteromer
P0DQD3;
2uzy42-741
Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes in... Heteromer
P0DQD3;
2uzx42-658
Crystal structure of Onartuzumab Fab in complex with MET and HGF-beta Heteromer
P14210;
NAG;4k3j39-564
Zymogen HGF-beta/MET with Zymogen Activator Peptide ZAP2.3 Heteromer
P14210;
4o3u39-564
Zymogen HGF-beta/MET with Zymogen Activator Peptide ZAP.14 Heteromer
P14210;
FUC;NAG;1PE;4o3t40-564
The Crystal Structure of HGF beta-chain in Complex with the Sema Domain of the Met Receptor. Heteromer
P14210;
1shy40-564
Crystal structure of Sema domain of the Met receptor in complex with FAB Heteromer
6i0441-517
Crystal structure of c-Cbl-TKB domain complexed with its binding motif in c-Met Heteromer
P22681;
3bux998-1005
'DIMER FORMATION THROUGH DOMAIN SWAPPING IN THE CRYSTAL STRUCTURE OF THE GRB2-SH2 AC-PYVNV COMPLEX' Heteromer
P08581; P62993;
1fyr1355-1359
Crystal structure of the c-Met kinase domain in complex with a pyrazolone inhibitorhomo-2-mer 75H;5t3q1050-1350
Crystal structure of c-Met in complex with pyrazolone inhibitor 26homo-2-mer 03X;3u6h1051-1351
Crystal structure of c-Met in complex with pyrazolone inhibitor 58ahomo-2-mer 044;3u6i1051-1351
Structure of c-Met with pyrimidone inhibitor 50homo-2-mer MT4;3efk1054-1351
Structure of c-Met with pyrimidone inhibitor 7homo-2-mer MT3;3efj1054-1351
CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN...homo-2-mer 5B4;5dg51050-1346
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibodymonomer GOL;84M;CL;5uab1029-1360
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibodymonomer CL;84P;5uad1029-1360
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibodymonomer CL;84P;5uaf1029-1360
Crystal structure of human c-Met kinase domain with its inhibitormonomer DF6;CL;3vw81024-1352
CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-METmonomer 1r1w1050-1360
Structure of MET receptor tyrosine kinase in complex with inhibitor SGX-523monomer SX8;CL;3dkf1050-1360
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met in...monomer KSA;1r0p1050-1360
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET in...monomer CKK;3c1x1050-1360
Structure of MET receptor tyrosine kinase in complex with ATPmonomer MG;ATP;CL;3dkc1051-1360
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in...monomer 320;3ctj1051-1360
c-Met Kinase in Complex with NVP-BVU972monomer CL;3QT;3qti1052-1360
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in...monomer 319;3cth1052-1360
Structure of Mutant(Y1248L) MET receptor tyrosine kinase in complex with inhibitor SGX-523monomer SX8;CL;3dkg1050-1356
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in...monomer L8V;3l8v1054-1360
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in...monomer 1FN;3ce31054-1360
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in...monomer 353;3f821055-1360
Crystal structure of c-Met in complex with LY2801653monomer L1X;4eev1045-1346
Structure of the apo MET receptor kinase in the dually-phosphorylated, activated statemonomer 3q6u1048-1348
Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-8033 analogmonomer 1JC;4iwd1048-1348
Structural Characterization of autoinhibited c-Met kinasemonomer 2g151046-1346
Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-2461 analogmonomer M61;3r7o1048-1348
Structure of dually-phosphorylated MET receptor kinase in complex with an MK-2461 analog with spe...monomer Q6W;3q6w1050-1348
Crystal structure of c-Met mutant Y1230H in complex with compound 14monomer 62E;CL;5hlw1057-1355
Human c-Met Kinase in complex with quinoxaline inhibitormonomer IHX;GBL;3f661052-1349
Crystal structure of the catalytic domain of c-Met kinase in complex with ARQ 197monomer M97;3rhk1049-1346
human c-MET kinase domain complexed with 6-benzyloxyquinoline inhibitormonomer IPA;DFQ;CL;3a4p1063-1360
Crystal structure of c-Met in complex with AMG 337monomer 5T1;5eyd1052-1348
Crystal structure of CMET in complex with novel inhibitormonomer DWF;4mxc1052-1346
Crystal structure of c-Met kinase domain in complex with LXM108monomer 66L;5hti1052-1346
Crystal structure of c-Met in complex with (R)-5-(8-fluoro-3-(1-fluoro-1-(3-methoxyquinolin-6-yl)...monomer 46G;4xmo1051-1345
Crystal structure of c-Met in complex with (S)-5-(8-fluoro-3-(1-(3-(2-methoxyethoxy)quinolin-6-yl...monomer 44X;4xyf1052-1346
Crystal structure of c-Met in complex with triazolopyridazine inhibitor 2monomer 0JJ;4deg1052-1346
Crystal structure of c-Met with triazolopyridazine inhibitor 13monomer B2D;3i5n1052-1346
x-ray structure of c-Met with inhibitor.monomer AM7;2rfn1057-1351
X-ray Structure of c-Met kinase in complex with inhibitor (S)-3-(1-(1H-pyrrolo(2,3-b)pyridin-3-yl...monomer 5TF;3zcl1052-1345
CRYSTAL STRUCTURE OF CMET WT with compound 3monomer 63B;5hni1063-1356
X-ray Structure of PF-04217903 bound to the kinase domain of c-Metmonomer KRW;3zxz1052-1345
Crystal structure of C-MET kinase domain in complex with 4-((6-(4- fluorophenyl)-(1,2,4)triazolo(...monomer F47;4ap71052-1345
CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH CMPD.monomer 63K;5ho61063-1356
Crystal structure of c-Met in complex with triazolopyridinone inhibitor 3monomer 0JK;4deh1053-1346
X-ray Structure of PF-02341066 bound to the kinase domain of c-Metmonomer VGH;2wgj1052-1345
Crystal structure of c-Met in complex with triazolopyridinone inhibitor 24monomer 0JL;4dei1053-1346
X-ray Structure of c-Met kinase in complex with inhibitor (S)-6-(1-(6- (1-methyl-1H-pyrazol-4-yl)...monomer W9Z;3zc51052-1345
Crystal structure of c-Met in complex with naphthyridinone inhibitor 5monomer 5SZ;5eyc1053-1345
Crystal structure of C-MET kinase domain in complex with 4-(3-((1H- pyrrolo(2,3-b)pyridin-3-yl)me...monomer 4K0;4aoi1052-1344
X-ray Structure of c-Met with triazolopyridazine Inhibitor.monomer L5G;3cd81054-1346
Structure of the kinase domain of c-Met bound to XL880 (GSK1363089)monomer 88Z;3lq81053-1345
Crystal structure of c-Met-M1250T in complex with SAR125844.monomer 63K;5hor1064-1356
X-ray structure of c-Met with triazolopyridazine inhibitor.monomer LKG;3ccn1055-1346
Human c-Met Kinase in complex with azaindole inhibitormonomer GBL;ZZY;2wd11055-1346
Crystal structure of c-Met L1195V in complex with SAR125844monomer 63K;5hoa1065-1356
'Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors'monomer GBL;3E8;4r1v1055-1345
Crystal structure of CMET in complex with novel inhibitormonomer 5QQ;5eob1055-1345
CRYSTAL STRUCTURE OF c-MET IN COMPLEX WITH NOVEL INHIBITORmonomer 6TD;5ya51057-1345
Crystal structure of C-MET kinase domain in complex with N'-((3Z)-4- chloro-7-methyl-2-oxo-1,2-di...monomer 6XP;3zze1059-1345
X-ray Structure of c-Met kinase in complex with inhibitor 6-((6-(4- fluorophenyl)-(1,2,4)triazolo...monomer 6XE;3zbx1059-1345
X-ray Structure of PHA-00665752 bound to the kinase domain of c-Metmonomer PFY;2wkm1059-1345
Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitormonomer 7PE;3EH;4r1y1062-1346
Crystal structure of cMET in complex with novel inhibitormonomer 0J8;4gg71064-1344
C-Met in complex with OSI ligandmonomer GBL;1RU;4knb1064-1344
Crystal structure of CMET in complex with novel inhibitormonomer 0J3;4gg51064-1344
X-ray structure of SU11274 bound to c-Metmonomer AM8;2rfs1067-1346
Solution structure of the PSI domain from the Met receptormonomer 1ssl519-562

Homology models

Oligo-stateLigandsQMEANTemplateRangeSeq id (%)ReportDownloadAssess
monomer -4.895l56.1.B44-919
25.63

Homology models built on isoform sequence

Isoform #Oligo-stateLigandsQMEANTemplateRangeSeq id (%)ReportDownloadAssess
2monomerMG;ATP;0.293dkc.1.A1069-1378
99.04
2monomer-1.854o3u.1.B39-564
100.00
3monomer-1.854o3u.1.B39-564
100.00
2monomer-2.892uzy.1.B42-741
99.72
3monomer-3.152uzy.1.B42-741
99.72